Apple is making another attempt to appeal the trade ban that forced it to remove the blood oxygen sensor from its smartwatches, Reuters reports. The company was forced to remove the feature in 2024, following a decision from the International Trade Commission (ITC) in 2023 that banned sales of the Apple Watch for violating health tech startup Masimo’s patents.
The US Court of Appeals for the Federal Circuit heard new arguments from Apple and Masimo’s lawyers on Monday over the legality of the original ITC ban. Apple’s argument is that the fact Masimo was developing its own smartwatch when Apple released the Apple Watch Series 6 in 2020 — the first of the company’s wearables with a blood oxygen sensor — shouldn’t be enough to justify the ban. Masimo disagrees.
The appeals court has heard the company’s arguments before, and even briefly paused the trade ban in December 2023 while the ITC considered Apple’s request for a longer pause. Ultimately, the ITC ruled in Masimo’s favor and denied Apple’s request. Apple removed the blood oxygen sensor in 2024 so it could restart sales of the Apple Watch Series 9 and Apple Watch Ultra 2 in the US.
The companies’ fight goes beyond just the blood oxygen sensor — Masimo’s smartwatches were, ironically, found to infringe on Apple patents — but clearly Apple is hung up on the feature. The company’s blood oxygen sensor was never as accurate as the pulse oximeters used in a doctor’s office, but it was part of a fairly comprehensive suite of heart health features on the smartwatch. It’s entirely possible Apple wants to reintroduce it in its watches as part of an even more ambitious health feature down the road.
